Nonviral therapeutic cell vaccine mediates potent antitumor effects

Vaccine

Volumn 24, Issue 18, 2006, Pages 3937-3945

  Moret Tatay, Inés ^a   Sanmartín, Isaías ^a   Marco, Francisco M ^b   Díaz, Joaquín ^b   Aliño, Salvador F ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b ASAC Pharma   (Spain)

Author keywords

Cell vaccines; Engineered cells; Nonviral vectors

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CANCER VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; LIPOPLEX; MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CELL BASED GENE THERAPY; CONTROLLED STUDY; DEATH; DNA MODIFICATION; DNA TRANSFECTION; DRUG EFFECT; DRUG POTENCY; DRUG USE; FEMALE; FROZEN SECTION; GENETIC ENGINEERING; IRRADIATION; MALE; MELANOMA; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROVOCATION TEST; SURVIVAL RATE; THAWING; TRANSGENE; VACCINATION;

ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL MEMBRANE; FATTY ACIDS, MONOUNSATURATED; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; QUATERNARY AMMONIUM COMPOUNDS; SURVIVAL ANALYSIS; TRANSFECTION;

EID: 33646493653     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.02.019     Document Type: Article

References (28)

1. Hall S.J., Kesina T.F., Trauger R., and Conley B.A. Gene therapy in the treatment of cancer. In: Kresina T.F. (Ed). An introduction to molecular medicine and gene therapy (2001), Wiley, New Jersey 235-262
2. Ward S., Casey D., Labarthe M.C., Whelan M., Dalgleish A., Pandha H., et al. Immunotherapeutic potential of whole tumour cells. Cancer Imunol Immunother 51 (2002) 351-357
3. Moret-Tatay I., Diaz J., Marco F.M., Crespo A., and Alino S.F. Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors. Cancer Gene Ther 10 (2003) 887-897
4. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95 (1998) 13141-13146
5. Parmiani G., Rodolfo M., and Melani C. Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal. Hum Gene Ther 11 (2000) 1269-1275
6. Khatami S., Brummer E., and Stevens D.A. Effects of granulocyte-macrophage colony stimulating factor (GM-CSF) in vivo on cytokine production and proliferation by spleen cells. Clin Exp Immunol 125 (2001) 198
7. Dranoff G. Tumour imunology immune reaction recognition and tumor protection. Curr Opin Immunol 14 (2002) 161-164
8. Asada H., Kishida T., Hirai H., Satoh E., Ohashi S., Takeuchi M., et al. Significant Antitumor Effects Obtained by Autologous Tumor Cell Vaccine Engineered to Secrete Interleukin (IL)-12 and IL-18 by Means of the EBV/Lipoplex. Mol Ther 5 (2002) 609-616
9. Moret I., Esteban Peris J., Guillem V.M., Benet M., Revert F., Dasi F., et al. Stability of PEI-DNA and DOTAP-DNA complexes: effect of alkaline pH, heparin and serum. J Control Release 76 (2001) 169-181
10. Alino S.F., Escrig E., Revert F., Guillem V.M., and Crespo A. Pharmacodynamic approach to study the gene transfer process employing nonviral vectors. Biochem Pharmacol 60 (2000) 1845-1853
11. Wu Q., Mahendran R., and Esuvaranathan K. Nonviral cytokine gene therapy on an orthotopic bladder cancer model. Clin Cancer Res 9 (2003) 4522-4528
12. Vieweg J., Boczkowski D., Roberson K.M., Edwards D.W., Philip M., Philip R., et al. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 55 (1995) 2366-2372
13. Gao X., and Huang L. Cationic liposome-mediated gene transfer. Gene Ther 2 (1995) 710-722
14. Larchian W.A., Horiguchi Y., Nair S.K., Fair W.R., Heston W.D., and Gilboa E. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy s dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin Cancer Res 6 (2000) 2913-2920
15. Botella-Estrada R., Malet G., Revert F., Dasi F., Crespo A., Sanmartin O., et al. Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor rnasin. Cancer Gene Ther 8 (2001) 278-284
16. Alino S.F. Long-term expression of the human alpha1-antitrypsin gene in mice employing anionic and cationic liposome vector. Biochem Pharmacol 54 (1997) 9-13 Review
17. Hilario E., Rodeno E., Simon J., Alvarez F.J., and Alino S.F. Differential uptake of systemic fluorochrome Hoechst 33342 in lung and liver metastasis of B16 melanoma. Virchows Arch A Pathol Anat Histopathol 421 (1992) 485-490
18. Clarke D.M., Baust J.M., Van Buskirk R.G., and Baust J.G. Chemo-cryo combination therapy: an adjuvant model for the treatment of prostate cancer. Cryobiology 42 (2001) 274-285
19. Jaffee E.M., Abrams R., Cameron J., Donehower R., Duerr M., Gossett J., et al. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther 9 (1998) 1951-1971
20. Todryk S.M., Birchall L.J., Erlich R., Halanek N., Orleans-Lindsay J.K., and Dalgleish A.G. Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines. Immunology 102 (2001) 190-198
21. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 90 (1993) 3539-3543
22. Borrello I., and Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 13 (2002) 185-193
23. Little S.R., Lynn D.M., Ge Q., Anderson D.G., Puram S.V., Chen J., et al. Poly-β ester-containing microparticles enhance the activity of nonviral genetic vaccines. Prac Natl Acad Sci USA 101 (2004) 9534-9539
24. Garg S., Oran A., Wajchman J., Sasaki S., Maris C.H., Kapp J.A., et al. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol 4 (2003) 907-912
25. Schmollinger J.C., and Dranoff G. Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy. Apoptosis 9 (2004) 309-313
26. Housseau F., Lindsey K.R., Oberholtzer S.D., Gonzales M.I., Boutin P., Moorthy A.K., et al. Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients. J Immunol Methods 266 (2002) 87-103
27. Stordeur P., Poulin L.F., Craciun L., Zhou L., Schandene L., de Lavareille A., et al. Cytokine mRNA quantification by real-time PCR. J Immunol Methods 259 (2002) 55-64
28. Blaya C., Crespo J., Crespo A., and Alino S.F. Anti-interleukin 4 antibody and indomethacin synergistic effect on B16 melanoma tumor progression. J Pharmacol Exp Ther 279 (1996) 472-477